These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6411994)

  • 1. Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration.
    Tolis G; Faure N; Koutsilieris M; Lemay A; Klioze S; Yakabow A; Fazekas AT
    J Steroid Biochem; 1983 Jul; 19(1C):995-8. PubMed ID: 6411994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the efficacy of subcutaneous and nasal spray buserelin treatment in suppression of testicular steroidogenesis in men with prostate cancer.
    Rajfer J; Handelsman DJ; Crum A; Steiner B; Peterson M; Swerdloff RS
    Fertil Steril; 1986 Jul; 46(1):104-10. PubMed ID: 3087785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.
    Warner B; Worgul TJ; Drago J; Demers L; Dufau M; Max D; Santen RJ
    J Clin Invest; 1983 Jun; 71(6):1842-53. PubMed ID: 6408125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine studies with a gonadotropin-releasing hormone analogue to achieve withdrawal of testosterone in prostate carcinoma patients.
    Wenderoth UK; Happ J; Krause U; Adenauer H; Jacobi GH
    Eur Urol; 1982; 8(6):343-7. PubMed ID: 6814918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?
    Borgmann V; Hardt W; Schmidt-Gollwitzer M; Adenauer H; Nagel R
    Lancet; 1982 May; 1(8281):1097-9. PubMed ID: 6122893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.
    Faure N; Labrie F; Lemay A; Bélanger A; Gourdeau Y; Laroche B; Robert G
    Fertil Steril; 1982 Mar; 37(3):416-24. PubMed ID: 6800852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
    Santen RJ; Warner B
    Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Testicular endocrine function in patients with prostatic cancer receiving medical castration by long-term administration of LH-RH agonists].
    Isurugi K; Kondo Y; Hirasawa K; Oyamatsu T; Honma Y
    Nihon Hinyokika Gakkai Zasshi; 1989 Oct; 80(10):1466-73. PubMed ID: 2513445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
    Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of a direct inhibitory effect of the gonadotropin-releasing hormone (GnRH) agonist D-Ser (TBU)6, des-Gly-NH2(10) GnRH ethylamide (Buserelin) on testicular steroidogenesis in men.
    Schaison G; Brailly S; Vuagnat P; Bouchard P; Milgrom E
    J Clin Endocrinol Metab; 1984 May; 58(5):885-8. PubMed ID: 6423662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.
    Tolis G; Ackman D; Stellos A; Mehta A; Labrie F; Fazekas AT; Comaru-Schally AM; Schally AV
    Proc Natl Acad Sci U S A; 1982 Mar; 79(5):1658-62. PubMed ID: 6461861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical and endocrinological studies of the luteinizing hormone-releasing hormone analogue therapy in prostatic cancer patients].
    Nagai A; Ohashi T; Irie S; Ohashi Y; Yamashita Y; Matsumura Y; Ohmori H; Tanahashi T; Nanba K
    Nihon Hinyokika Gakkai Zasshi; 1989 Jun; 80(6):891-8. PubMed ID: 2529389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma.
    Santen RJ; Demers LM; Max DT; Smith J; Stein BS; Glode LM
    J Clin Endocrinol Metab; 1984 Feb; 58(2):397-400. PubMed ID: 6420439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (Hoe-766) in young normal adult men.
    Faure N; Labrie F; Belanger A; Lemay A; Raynaud JP; Von der Ohe M; Fazekas AT
    J Endocrinol Invest; 1982; 5(6):355-60. PubMed ID: 6820372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone and its agonist inhibit testicular luteinizing hormone receptor and steroidogenesis in immature and adult hypophysectomized rats.
    Bambino TH; Schreiber JR; Hsueh AJ
    Endocrinology; 1980 Oct; 107(4):908-17. PubMed ID: 6250797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
    Huhtaniemi I; Nikula H; Rannikko S
    J Clin Endocrinol Metab; 1985 Oct; 61(4):698-704. PubMed ID: 2993345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
    Wenderoth UK; Jacobi GH
    Prog Clin Biol Res; 1985; 185A():297-305. PubMed ID: 3162176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
    Pettersson B; Varenhorst E; Petas A; Sandow J
    Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. II. Endocrinology and histology of the testis.
    Huhtaniemi I; Nikula H; Parvinen M; Rannikko S
    J Androl; 1987; 8(6):363-73. PubMed ID: 3123446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of testicular steroidogenesis by gonadotropin-releasing hormone agonists and antagonists.
    Huhtaniemi I; Nikula H; Rannikko S; Clayton R
    J Steroid Biochem; 1986 Jan; 24(1):169-76. PubMed ID: 3009972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.